Clinical Research Advantage and Quintiles Strategic Alliance Drives Study Participation with Emphasis on Safety, Study Efficiencies and Quality Data

TEMPE, Ariz.--(BUSINESS WIRE)--Clinical Research Advantage (CRA), the country’s largest community-based network of clinical trial sites, has entered into a strategic agreement with Quintiles to facilitate a higher level of clinical trial participation with an emphasis on safety, improved study efficiencies and excellent quality data in medical research. Clinical Research Advantage is the first therapeutically aligned network of Family Medicine community-based sites selected by Quintiles as a strategic alliance.

“The core value and principal purpose of Clinical Research Advantage is to improve the lives of patients through the development of new medical therapies. Working with Quintiles will allow CRA to conduct an increased number of community-based trials with unparalleled accuracy and safety.”

“It is an honor to be chosen by Quintiles, the world’s largest biopharmaceutical services provider, with the highest standards for quality and safety,” said Mark S. Hanley, CRA’s Chief Executive Officer. “The core value and principal purpose of Clinical Research Advantage is to improve the lives of patients through the development of new medical therapies. Working with Quintiles will allow CRA to conduct an increased number of community-based trials with unparalleled accuracy and safety.”

“Clinical Research Advantage impressed us with their high standards for quality, high patient enrollments and exceptional study start-up abilities,” said Lindy Jones, Senior Vice President, Integrated Site Services, Quintiles. “Many chronic conditions such as diabetes and heart disease are now managed in the community. It is imperative that these patient populations have the opportunity to participate in studies and be a part of the quest to develop new and better medicines for conditions that have a significant impact on both individuals and society. We are pleased to enter into this relationship with CRA and anticipate that together we will ensure that studies start on the right path.”

The CRA-Quintiles relationship marks a new era in Phase II-IV clinical trials, enabling physicians and clinical researchers to conduct an increased number of trials across a wide range of disease areas. In addition, it will streamline and expedite the process of bringing these potentially life-changing and life-saving drugs to market.

About Clinical Research Advantage

Tempe, Ariz.-based Clinical Research Advantage, Inc. (CRA) is a provider of a range of research services to pharmaceutical companies and clinical research organizations. As a leading trial management organization, CRA operates from 38 sites across 17 geographic markets nationwide, helping trial sponsors bring drugs to market more quickly and efficiently. Founded in 1992, CRA has successfully completed more than 1,800 clinical trials on behalf of its clients. For more information: www.crastudies.com